Occam Global is an international executive recruiting and leadership advisory firm specializing in building management teams for innovative companies in the life sciences, AI, robotics, defense, technology, and venture capital sectors.
The firm’s unique competence lies in a proven ability to attract exceptional business and scientific leaders, fluid access to uncommon talent, and an enduring commitment to results informed by elevated ethics and enlightened aggression.
As a result, Occam has established itself as a leading search partner for entrepreneurs, investors, and corporations globally. Our success is rooted in cultivating and valuing relationships, establishing trust with entrepreneurs, executives, and investors, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.
Each in our own fashion, we sat in the mud in 2012. I had just retired from a 25-year career at Fidelity Investments and moved from Boston to New York. John had just completed his MBA without much of a clue as to how to build his career anew after having toiled for a decade on Wall Street.
With common resolution, an intergenerational conspiracy was hatched, one which allowed us to reinvent ourselves. We reached for the stars in creating a family business. I would find a new creative platform to ply a trade honed over three decades in Boston and John would get a fresh start in a business which he had witnessed me practice throughout his youth.
Thus, Occam was born. A fusion of hard-earned wisdom and amorphous creative vigor. Our collaboration has yielded a richly successful global search firm, one dedicated to helping entrepreneurs realize their vision. Occam’s culture is rooted in intuitive team play, mutual respect, warmth of spirit, uncompromising ethics and clarity of purpose – family values.
We built our firm on the pillars of objectivity, undiluted ethics, and enlightened aggression.
With a process that’s rooted in relationships, data, and intellect, we’ve provided professional judgments that have made a lasting impact on our partners.
Our judgements are simultaneously inspired by instinct and pragmatism, resulting in balanced outcomes designed to endure.
New York City-based executive search firm Occam Global has assisted in the recruitment of Troy Lionberger as chief business officer of biotechnology company A-Alpha Bio. “Troy brings a rare blend of deep technical fluency and commercial creativity,” said David Younger, co-founder and CEO of A-Alpha Bio. “His track record speaks for itself—from inventing platform applications to
New York City-based recruitment firm Occam Global has placed Emile Nuwaysir as president, chief executive officer and member of the board of directors of gene therapy company Ensoma. In conjunction with the CEO appointment, Ensoma executive chairman Paula Soteropoulos will transition to the role of chairman of the board, and Kush M. Parmar, managing partner
In December 2025, Occam Global, a leading executive recruiting firm specializing in the life sciences, recruited obesity and commercial veteran Chris Boulton as CEO of Prolynx. Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced the closing of a $70 million Series A financing co-led by 5AM Ventures and OrbiMed, along
In November 2025, Occam Global, a leader in executive recruiting for the life sciences, placed Laurent Fischer, MD, as the first independent Chairman of the Board of Directors of Shinobi Therapeutics. Fischer brings over 30 years of senior leadership experience in biotechnology to Shinobi, with a proven track record of building, growing, and exiting companies focused on innovative therapies. His
In March 2026, Occam Global, a leader in executive recruiting for TechBio, appointed Marcus Schindler, PhD, to Cradle’s Advisory Board. Cradle is an AI-powered protein engineering company accelerating innovation across the life sciences. Schindler most recently served as Executive Vice President and Chief Scientific Officer at Novo Nordisk, where he led global research and early development across major therapeutic
In June 2025, Occam Global placed Paul Burton, MD, PhD, on the Board of Moonwalk Biosciences. Burton became Amgen’s CMO in June 2023. Prior to joining Amgen, he served as the CMO of Moderna Therapeutics from 2021 to 2023 and spent 16 years at J&J, where his most recent role was Chief Global Medical Affairs
Case Studies
Read about how Occam Global is helping innovative organizations tackle their biggest executive recruitment challenges
Blog & Insights
Discover new tips, industry news and guides by Occam Global
-Latest Interview: Whit Bernard, CEO of Metsera